The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

Coronary Artery Disease Clinical Trial

— PLATINUM LL  

Official title:

PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Long Lesion Sub-trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01500434
• Other study ID #: S2046C
• Status: Completed
• Phase: Phase 3
• Start date: February 2009
• Est. completion date: May 2015

Study information

• Verified date: March 2019
• Source: Boston Scientific Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. The lesions can be longer than average-sized.

Description:

The wide-spread use of drug-eluting stents (DES) has evolved as standard of care in de novo lesions. The proposed study will evaluate the safety and effectiveness of PROMUS Element for the treatment of de novo atherosclerotic lesions in native coronary arteries. The study design is consistent with the draft guidance for industry titled, "Coronary Drug-Eluting Stents - Nonclinical and Clinical Studies" (March 2008).

During the trial, thienopyridines must be administered according to the 2007 American College of Cardiology (ACC)/American Heart Association (AHA)/Society for Cardiovascular Angiography and Interventions (SCAI) guidelines, which recommended that clopidogrel (75 mg daily) or ticlopidine (250 mg twice daily) be prescribed after stent implantation for at least 6 months in all patients, and for at least 12 months in patients who are not at high risk of bleeding. For sites in the United States, the use of prasugrel is not allowed as part of the PLATINUM Clinical Trial. For sites in other countries, prasugrel may be prescribed according to its approved dosing in countries in which it is available. For patients taking aspirin daily a loading dose is recommended; for patients who have not been taking aspirin daily, aspirin must be administered as a loading dose. Patients continue to take aspirin indefinitely to reduce the risk of thrombosis.

This PLATINUM Long Lesion study is a sub-trial associated with the PLATINUM Workhorse Randomized Controlled Trial, which is registered under NCT00823212.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 102
• Est. completion date: May 2015
• Est. primary completion date: March 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient must be at least 18 years of age

• Patient (or legal guardian) understands study requirements and treatment procedures and provides written informed consent before any study-specific tests or procedures are performed

• For patients less than 20 years of age enrolled at a Japanese site, patient and patient's legal representative must provide written informed consent before any study-specific tests or procedures are performed

• Patient is eligible for percutaneous coronary intervention (PCI)

• Patient has documented stable angina pectoris or documented silent ischemia; or unstable angina pectoris

• Patient is an acceptable candidate for coronary artery bypass grafting (CABG)

• Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30 days prior to enrollment

• Patient is willing to comply with all protocol-required follow-up evaluations

Angiographic Inclusion Criteria (visual estimate):

• Target lesion must be a de novo lesion >24 mm and =34 mm in length (by visual estimate) in a native coronary artery =2.50 mm to =4.25 mm in diameter (by visual estimate). Target lesion must be in a major coronary artery or branch with visually estimated stenosis >=50% and <100% with Thrombolysis in Myocardial Infarction (TIMI) flow >1.

Exclusion Criteria:

• Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute MI

• Patient has had a known diagnosis of recent MI (ie, within 72 hours prior to index procedure) and has elevated enzymes at time of index procedure as follows.

• Patients are excluded if any of the following criteria are met at time of the index procedure.

• If CK-MB >2× upper limit of normal (ULN), the patient is excluded regardless of CK Total.

• If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.

• If CK Total/CK MB are not used and Troponin is, patients are excluded if the following criterion is met at time of index procedure.

• Troponin >1× ULN with at least one of the following.

• Patient has ischemic symptoms and ECG changes indicative of ongoing ischemia (eg, >1 mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);

• Development of pathological Q waves in the ECG; or

• Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.

Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK MB (or Troponin if CK Total/CK MB are not used) must be documented prior to enrolling/randomizing the patient.

• Patient has received an organ transplant or is on a waiting list for an organ transplant

• Patient is receiving or scheduled to receive chemotherapy within 30 days before or after index procedure

• Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)

• Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin, coumadin) for indications other than acute coronary syndrome

• Patient has platelet count <100,000 cells/mm3 or >700,000 cells/mm3

• Patient has white blood cell (WBC) count <3,000 cells/mm3

• Patient has documented or suspected liver disease, including laboratory evidence of hepatitis

• Patient is on dialysis or has known renal insufficiency (ie, estimated creatinine clearance <50 ml/min by the Cockcroft Gault formula, or [(140-age)*lean body weight (in kg)]/[plasma creatinine (mg/dl)*72])

• Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions

• Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol

• Target vessel(s) or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to index procedure

• Target vessel(s) has been treated within 10 mm proximal or distal to target lesion (by visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) at any time prior to index procedure

• Non-target vessel or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to index procedure

• Planned or actual target vessel(s) treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter immediately prior to stent placement

• Planned PCI or CABG after index procedure

• Patient previously treated at any time with coronary intravascular brachytherapy

• Patient has a known allergy to the study stent system or protocol-required concomitant medications (eg, stainless steel, platinum, cobalt, chromium, nickel, tungsten, acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot be adequately premedicated

• Patient has active peptic ulcer or active gastrointestinal (GI) bleeding

• Patient has one of the following.

• Other serious medical illness (eg, cancer, congestive heart failure) that may reduce life expectancy to less than 24 months

• Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)

• Planned procedure that may cause non-compliance with protocol or confound data interpretation

• Patient is participating in another investigational drug or device clinical trial that has not reached its primary endpoint

• Patient intends to participate in another investigational drug or device clinical trial within 12 months after index procedure

• Patient with known intention to procreate within 12 months after index procedure (Women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure.)

• Patient is a woman who is pregnant or nursing (A pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)

• Patient has more than 2 target lesions, or more than 1 target lesion and 1 non-target lesion, which will be treated during the index procedure

Angiographic Exclusion Criteria (visual estimate):

• Target lesion meets any of the following criteria:

• Aorto-ostial location (ie, lesion located within 5 mm of ostium by visual estimate)

• Left main location

• Located within 5 mm of origin of the left anterior descending (LAD) coronary artery or left circumflex (LCX) coronary artery by visual estimate

• Located within a saphenous vein graft or arterial graft

• Will be accessed via a saphenous vein graft or arterial graft

• Involves a side branch >=2.0 mm in diameter by visual estimate

• Involves a clinically significant side branch <2.0 mm in diameter by visual estimate that has a clinically significant stenosis at the ostium

• TIMI flow 0 (total occlusion) or TIMI flow 1 prior to wire crossing

• Excessive tortuosity proximal to or within the lesion

• Extreme angulation proximal to or within the lesion

• Target lesion and/or target vessel proximal to the target lesion is moderately to severely calcified by visual estimate

• Restenotic from previous intervention

• Thrombus, or possible thrombus, present in target vessel

• Non-target lesion to be treated during the index procedure meets any of the following criteria:

• Located within the target vessel

• Located within a bypass graft (venous or arterial)

• Left main location

• Chronic total occlusion

• Involves a complex bifurcation (eg, bifurcations requiring treatment with more than 1 stent)

• Restenotic from previous intervention

• Patient has unprotected left main coronary artery disease (>50% diameter stenosis)

• Patient has protected left main coronary artery disease and a target lesion in the LAD or LCX

• Patient has an additional clinically significant lesion(s) in target vessel for which an intervention within 12 months after the index procedure is likely to be required

• Patient has 2 target lesions in the same vessel that are separated by less than 15 mm (by visual estimate) Note: Multiple focal stenoses will be considered as a single lesion if they can be completely covered with 1 stent.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• PROMUS Element Coronary Stent System
PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).

Drug:
• Aspirin
Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
• Thienopyridine
Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.

Locations

Country	Name	City	State
Australia	Monash Medical Centre	Clayton	Victoria
Australia	St. Vincents Public,	Fitzroy	Victoria
Belgium	Ziekenhuis Oost Limburg	Genk
Belgium	UZ Gasthuisberg	Leuven
France	Clinique Pasteur	Toulouse
Japan	Shonan Kamakura General Hospital	Kamakura-shi	Kanagawa-ken
Japan	Sakurabashi Watanabe Hospital	Osaka-shi	Osaka
Latvia	P. Stradins University Hospital	Riga
New Zealand	North Shore Hospital	Takapuna
United States	Ohio Health Research and Innovation Institute	Columbus	Ohio
United States	Ohio State University Medical Center	Columbus	Ohio
United States	Moses H. Cone Memorial Hospital/LeBauer Cardiovascular Research Foundation	Greensboro	North Carolina
United States	Jackson-Madison County General Hospital	Jackson	Tennessee
United States	Scripps Clinic	La Jolla	California
United States	Abbott Northwestern Hospital	Minneapolis	Minnesota
United States	Columbia University Medical Center	New York	New York
United States	MediQuest Research Group Inc. at Munroe Regional Medical Center	Ocala	Florida
United States	Oklahoma Foundation for Cardiovascular Research	Oklahoma City	Oklahoma
United States	Florida Hospital	Orlando	Florida
United States	Northern Michigan Hospital	Petoskey	Michigan
United States	Maine Medical Center	Portland	Maine
United States	Providence St. Vincent Medical Center	Portland	Oregon
United States	Wake Medical Center	Raleigh	North Carolina
United States	William Beaumont Hospital	Royal Oak	Michigan
United States	Mercy General Hospital	Sacramento	California
United States	TexSAn Heart Hospital	San Antonio	Texas
United States	Alvarado Hospital	San Diego	California
United States	Providence Health & Services - Washington	Spokane	Washington
United States	Mercy St. Vincent Medical Center	Toledo	Ohio
United States	North Mississippi Medical Center	Tupelo	Mississippi

Sponsors (1)

Lead Sponsor	Collaborator
Boston Scientific Corporation

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  France,  Japan,  Latvia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Target Lesion Failure (TLF)	Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.	12 months
Secondary	Target Lesion Failure (TLF)	TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.	30 Days
Secondary	Target Lesion Failure (TLF)	TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.	6 Months
Secondary	Target Vessel Failure (TVF)	TVF is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.	30 Days
Secondary	Target Vessel Failure (TVF)	TVF is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.	6 months
Secondary	Target Vessel Failure (TVF)	TVF is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.	12 months
Secondary	All Cause Death		30 Days
Secondary	All Cause Death		6 months
Secondary	All Cause Death		12 months
Secondary	Cardiac Death Related to the Target Vessel	Cardiac death is defined as Death due to any of the following: acute MI; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded	30 Days
Secondary	Cardiac Death Related to the Target Vessel	Cardiac death is defined as Death due to any of the following: acute MI; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded	6 months
Secondary	Cardiac Death Related to the Target Vessel	Cardiac death is defined as Death due to any of the following: acute MI; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded	12 months
Secondary	Myocardial Infarction (MI) Related to the Target Vessel	New Q-waves in =2 leads lasting =0.04 sec with creatine kinase-myoglobin band (CK-MB) or troponin >normal; if no new Q-waves total CK levels >3×normal (peri-percutaneous coronary intervention[PCI]) or >2×normal (spontaneous) with elevated CK-MB or troponin >3×normal (peri-PCI) or >2×normal (spontaneous) plus at least 1 of the following: ECG changes showing new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin >5×normal	30 Days
Secondary	Myocardial Infarction (MI) Related to the Target Vessel	New Q-waves in =2 leads lasting =0.04 sec with creatine kinase-myoglobin band (CK-MB) or troponin >normal; if no new Q-waves total CK levels >3×normal (peri-percutaneous coronary intervention[PCI]) or >2×normal (spontaneous) with elevated CK-MB or troponin >3×normal (peri-PCI) or >2×normal (spontaneous) plus at least 1 of the following: ECG changes showing new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin >5×normal	6 months
Secondary	Myocardial Infarction (MI) Related to the Target Vessel	New Q-waves in =2 leads lasting =0.04 sec with creatine kinase-myoglobin band (CK-MB) or troponin >normal; if no new Q-waves total CK levels >3×normal (peri-percutaneous coronary intervention[PCI]) or >2×normal (spontaneous) with elevated CK-MB or troponin >3×normal (peri-PCI) or >2×normal (spontaneous) plus at least 1 of the following: ECG changes showing new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin >5×normal	12 months
Secondary	Target Lesion Revascularization (TLR)	TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.	30 days
Secondary	Target Lesion Revascularization (TLR)	TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.	6 months
Secondary	Target Lesion Revascularization (TLR)	TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.	12 months
Secondary	Target Vessel Revascularization (TVR)	TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.	30 days
Secondary	Target Vessel Revascularization (TVR)	TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.	6 months
Secondary	Target Vessel Revascularization (TVR)	TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.	12 months
Secondary	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition	DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)	24 hours
Secondary	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition	DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)	>24 hours-30 days
Secondary	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition	DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)	31-365 days
Secondary	Acute Technical Success	Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent	Index Procedure
Secondary	Clinical Procedural Success	Defined as mean lesion diameter stenosis <30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital MI, TVR, or cardiac death	In hospital (average of 1-2 days post index procedure)